Arkuda Therapeutics - Crunchbase Company Profile & Funding

Q: Who invested in Arkuda Therapeutics?

Arkuda Therapeutics has 9 investors including Cormorant Asset Management And Pivotal bioVenture Partners.

Q: How much funding has Arkuda Therapeutics raised to date?

Arkuda Therapeutics has raised obfuscated.

Overview

Arkuda Therapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Events

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Arkuda Therapeutics

CB Rank

47751

Arkuda Therapeutics is a pharmaceutical company.

Founded

obfuscation

Private

Series B

Cambridge, Massachusetts, United States

11-50

www.arkudatx.com/

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Funding Rounds

Series B

OBF

obfuscation

Grant

OBF

obfuscation

Series A

OBF

obfuscation

Key People

Johannes Fruehauf: Investor, Board Member
Past Role: ViThera, Co-Founder, Chairman
Gerhard Koenig: Founder & CEO

Details

Legal Name

Arkuda Therapeutics Inc.

Operating Status

Active

Company Type

For Profit

Founders

Duane Burnett, Gerhard Koenig

About the Company

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined

subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.

Phone Number

857-201-2789

Contact Email

info@arkudatx.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Discovering therapies for neurodegenerative diseases

Arkuda Therapeutics focuses on developing treatments aimed at altering the course of neurodegenerative diseases like Alzheimer’s, Parkinson’s, and frontotemporal dementia.

Applying lysosomal biology expertise

The company utilizes its deep understanding of lysosomal biology to address neurodegenerative conditions, targeting cellular recycling and homeostasis to maintain normal neuronal function.

Research & Development

Arkuda Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B
obfuscated obfuscation	Series B - Arkuda Therapeutics	8	obfuscated obfuscation	Cormorant Asset Management, Pivotal bioVenture Partners	Series B

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Cormorant Asset Management	Yes	Series B - Arkuda Therapeutics	Raymond Kelleher
Cormorant Asset Management	Yes	Series B - Arkuda Therapeutics	Raymond Kelleher
Cormorant Asset Management	Yes	Series B - Arkuda Therapeutics	Raymond Kelleher
Cormorant Asset Management	Yes	Series B - Arkuda Therapeutics	Raymond Kelleher
Cormorant Asset Management	Yes	Series B - Arkuda Therapeutics	Raymond Kelleher